Aimovig

Erenumab, sold under the brand name Aimovig, is a medication which targets the calcitonin gene-related peptide receptor (CGRPR) for the prevention of migraine.[2][3][4] Erenumab was approved in May 2018 and was the first of a group of four CGRPR antagonists to be approved by the U.S. Food and Drug Administration (FDA) that year. It is a form of monoclonal antibody therapy in which antibodies are used to block the receptors for the protein CGRP, ... [wikipedia]